Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nutrigenomics Start-Ups

This article was originally published in Start Up

Executive Summary

Paths to commercialization are uncertain in nutrigenomics, an emerging science which seeks to identify gene-food interactions that differ among subpopulations and between individuals and to personalize diets to prevent disease.

You may also be interested in...



NutraGenomics Inc.

NutraGenomics Inc. is using a systems approach to identify diet-responsive genes and SNPs involved in chronic diseases such as Type 2 diabetes, obesity, atherosclerosis, and certain cancers, using proprietary mouse models to examine dietary effects on genes, proteins, transcription, and metabolism.

WellGen Inc.

These days, consumers reach for calcium-fortified orange juice to keep bones healthy, whole-grain Cheerios that reduce the risk of heart disease and cancer, and bags of walnuts that advertise Omega 3, for heart health. The founders of WellGen believe the time is right to push the frontier of food science into medicine. With a patent from Rutgers University, WellGen will screen food substances against genes implicated in diseases.

AlphaGenics Inc.

AlphaGenics is launching a consumer-focused nutrigenomics business. It will track its client's diets and compare their food intake to changes in their gene expression, over time building a database that the company believes will become a valuable research tool for advancing the emerging science of nutrigenomics.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel